Who We Are

King Pharmaceuticals, Inc. established King Pharmaceuticals Canada in 2006 with the goal of applying our resources and capabilities to help meet Canada's healthcare needs. Our Canadian presence provides a unique opportunity to better understand Canada's healthcare environment so that we may continuously help improve the wellbeing of Canadians.

King Pharmaceuticals Canada is headquartered in the Canadian pharmaceutical hub of Mississauga, Ontario, Canada. This location provides us with a central location for distributing and selling pharmaceutical products throughout Canada.

King Pharmaceuticals, Inc.

King Pharmaceuticals^® began operations in January 1994, after purchasing the company's Bristol Tennessee facility and assuming contracts to manufacture prescription pharmaceutical products for such prominent companies as SmithKline Beecham Corporation, predecessor to GlaxoSmithKline, and Novartis.

For the next ten years, King principally focused on the manufacture, acquisition, and marketing of previously approved products. Under new leadership, the company shifted its strategy to position itself to become a leading developer and acquirer of novel branded pharmaceutical products in later stages of development, focusing on three main therapeutic areas, cardiovascular/metabolics, neuroscience and hospital/acute care.

King's labor force has grown from an initial 145 to approximately 2900 employees involved in every discipline of a major pharmaceutical company, including sales and marketing, research and development, regulatory affairs, quality management, and manufacturing.

Sales and Marketing

As the company has grown, so have its marketing capabilities. Today, King's dedicated field sales force includes more than 1100 individuals in the U.S., Canada and Puerto Rico.

Research and Development

King's approximately 100-person strong in-house R&D team includes drug development scientists, regulatory and drug safety staff who manage the full range of R&D activities for late-stage products: drug discovery, clinical development, drug safety, regulatory affairs, medical affairs and project management. Additionally, King has established a highly cost-effective, readily scalable, R&D model that sets it apart from other pharmaceutical companies.

Manufacturing

King currently operates manufacturing facilities - in Bristol, Tennessee, Rochester, Michigan, St. Louis, Missouri, St. Petersburg, Florida, and Middleton, Wisconsin - that produce a broad array of dosage forms including tablets, capsules, liquids, suspensions, solutions, suppositories, creams, ointments, injectables, auto-injector products, and other drug products.

Financial Highlights

King's revenues have grown from $13 million in 1994 to nearly $2.0 billion in 2006. King's common stock trades on the New York Stock Exchange under the symbol "KG", and is a component of the S&P 500 Index and the AMEX pharmaceutical index.

Relying on talented and dedicated employees, following a strategic vision, and developing trusted relationships with other drug companies, wholesalers, physicians and pharmacists, King is redefining the standards for success in pursuing opportunities in the health care industry. The Company looks forward to continuing its exciting growth and sharing its success with its stakeholders and employees.

About Forward-Looking Statement

The foregoing contains forward-looking statements, which reflect management's current views of future events and operations, including, but not limited to, statements pertaining to King's future growth. These forward-looking statements involve certain significant risks and uncertainties, and actual results may differ materially from the forward-looking statements. Some important factors, which may cause results to differ include those discussed in the "Risk Factors" section and other sections of King's Form 10-K for the year ended December 31, 2006, and King's Form 10-Q for the quarter ended June 30, 2007, which are on file with the Securities and Exchange Commission. To view risk factors pertaining to forward-looking statements, click on the following link: Risk Factors. King does not undertake to publicly update or revise any of its forward-looking statements even if experience or future changes show that the indicated results or events will not be realized.